Quote | Cyclo Therapeutics Inc. (NASDAQ:CYTH)
Last: | $1.40 |
---|---|
Change Percent: | 1.38% |
Open: | $1.3511 |
Close: | $1.40 |
High: | $1.4 |
Low: | $1.33 |
Volume: | 21,590 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Cyclo Therapeutics Inc. (NASDAQ:CYTH)
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
2024-03-19 06:53:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclo Therapeutics (NASDAQ: CYTH ) just reported results for the fourth quarter of 2023. Cyclo Therapeutics reported earnings per share of -23 cents. The company repor...
Message Board Posts | Cyclo Therapeutics Inc. (NASDAQ:CYTH)
Subject | By | Source | When |
---|---|---|---|
The now | Pedro2004 | investorshub | 05/01/2023 1:32:07 PM |
$CYTH Price trading up | tradrdad45 | investorshub | 04/30/2023 12:40:36 AM |
$CYTH MomentumIts gaining | Covid19freak | investorshub | 04/27/2023 7:53:22 AM |
$CYTH MomentumIts trading | pay in cash | investorshub | 04/26/2023 6:17:37 PM |
is it bear time? Or do we go bull? | Esa | investorshub | 04/20/2023 10:15:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...